|1.29||0.00 / 0.00%|
Data as of Jan 28
|1.24||-0.05 / -3.88%|
The 2 analysts offering 12-month price forecasts for Peregrine Pharmaceuticals Inc have a median target of 4.25, with a high estimate of 5.00 and a low estimate of 3.50. The median estimate represents a +229.46% increase from the last price of 1.29.
The current consensus among 2 polled investment analysts is to Buy stock in Peregrine Pharmaceuticals Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.